Navigation Links
Micromet, Inc. Reports Third Quarter 2008 Financial Results
Date:11/6/2008

o be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials; the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial; the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data; the risk that we or our collaborators will not obtain approval to market our product candidates; the risks associated with reliance on outside financing to meet capital requirements; and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These and other risk factors are more fully discussed under "Risk Factors" in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by Micromet with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

(Tables Follow)

Micromet, Inc.

Condensed Consolidated Balance Sheets


'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
2. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
3. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. EntreMed Reports Third Quarter 2008 Financial Results
9. CV Therapeutics Reports 2008 Third Quarter Financial Results
10. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
11. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Middle East & Africa Biomedical Sensors Market ... their offering. The Middle ... estimated at $0.84 billion by 2018 at a CAGR ... near future will bring Biomedical sensors that are adaptable ...
(Date:8/31/2015)... MARLBOROUGH, Mass. , Aug. 31, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today announced that the 30-day review period ... Drug (IND) for ocular indications with the U.S. ... the IND is now active. ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... 4, 2010 -- Thin layers of oxide materials and their ... the first time by researchers at the Center for Nanophase ... Laboratory, providing new insight into the complicated link between their ... ability to see in color, or in 3-D," said the ...
... Aug. 4 Forte, LLC, today ... web-based probate database and estate recovery application that ... Finder OnDemand provides access to a proprietary database ... powerful matching algorithms that accurately match deceased accounts ...
... Aug. 4 New England Biolabs is ... Genome Sciences Center has selected New England Biolabs as ... construction reagents. NEBNext DNA Sample Prep Reagent Sets contain ... for sample preparation for next generation sequencing, as well ...
Cached Biology Technology:Unprecedented look at oxide interfaces reveals unexpected structures on atomic scale 2Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 3
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... and Edythe L. Broad Institute of Harvard and MIT ("the ... from the Boston-based Klarman Family Foundation to support a new ... This grant will allow the scientific community to ... health and disease, paving the way for major treatment breakthroughs. ...
... new system for delivering a drug to organ transplant patients, ... being developed by scientists at the University of Strathclyde in ... transplant operations and helps prevent the patient,s body rejecting the ... which the most serious problems are kidney and liver damage, ...
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
Cached Biology News:Broad Institute awarded $32.5 million grant to launch new 'Cell Observatory' 2Broad Institute awarded $32.5 million grant to launch new 'Cell Observatory' 3System to deliver organ transplant drug -- without harmful side effects 2Biometrics Market in India 2010 - 2014 2
... Fragment, Exonuclease Minus, is a DNA-dependent DNA ... the 3´→5´ exonuclease activities present in intact ... is used for random primer labeling (3,4) ... Fragment, Exonuclease Minus, will leave a single-base ...
SMVT (N-14)...
...
... Dideoxycytidine is a cytidine analog that has ... activity. Immunogen: Chemical / Small ... The specificity of the ddC antiserum was determined ... ddC to moles of ddC analog at the ...
Biology Products: